Elite Pharmaceuticals (ELTP) News Today $0.62 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Elite Pharmaceuticals (OTCMKTS:ELTP) Receives FDA Approval for Generic Vyvanse®November 20, 2024 | americanbankingnews.comElite Pharmaceuticals Gains FDA Approval for Generic VyvanseNovember 19, 2024 | markets.businessinsider.comElite Pharmaceuticals, Inc. (PNK:ELTP) Q2 2025 Earnings Call TranscriptNovember 18, 2024 | msn.comElite Pharmaceuticals, Inc. (ELTP) Q2 2025 Earnings Conference Call TranscriptNovember 16, 2024 | seekingalpha.comElite Pharmaceuticals Reports Strong Q2 2025 Financial ResultsNovember 16, 2024 | markets.businessinsider.comElite Pharmaceuticals, Inc. (OTCMKTS:ELTP) Sees Large Decrease in Short InterestElite Pharmaceuticals, Inc. (OTCMKTS:ELTP - Get Free Report) was the recipient of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 1,560,500 shares, a drop of 22.1% from the October 15th total of 2,004,100 shares. Based on an average daily trading volume, of 14,522,600 shares, the short-interest ratio is currently 0.1 days.November 15, 2024 | marketbeat.comElite Pharmaceuticals Inc (ELTP) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...October 9, 2024 | finance.yahoo.comShort Interest in Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP) Grows By 10.5%Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP - Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 1,834,800 shares, a growth of 10.5% from the August 15th total of 1,661,100 shares. Based on an average daily trading volume, of 5,263,800 shares, the short-interest ratio is presently 0.3 days.September 18, 2024 | marketbeat.comElite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate SodiumAugust 27, 2024 | finanznachrichten.deElite Pharmaceuticals (OTCMKTS:ELTP) Stock Price Passes Above 50 Day Moving Average of $0.19Elite Pharmaceuticals (OTCMKTS:ELTP) Share Price Crosses Above 50-Day Moving Average of $0.19August 27, 2024 | marketbeat.comElite Pharmaceuticals, Inc. (OTCMKTS:ELTP) Sees Significant Decrease in Short InterestElite Pharmaceuticals, Inc. (OTCMKTS:ELTP - Get Free Report) saw a significant drop in short interest in July. As of July 31st, there was short interest totalling 1,581,500 shares, a drop of 9.2% from the July 15th total of 1,740,800 shares. Based on an average trading volume of 1,104,200 shares, the days-to-cover ratio is currently 1.4 days.August 18, 2024 | marketbeat.comELITE PHARMACEUTICALS INCAugust 16, 2024 | msn.comELTP Stock Earnings: Elite Pharmaceuticals Reported Results for Q1 2025August 14, 2024 | investorplace.comIntercontinental Exchange Inc (IC2.BE)July 21, 2024 | nz.finance.yahoo.comELTP Stock Earnings: Elite Pharmaceuticals Reported Results for Q4 2024July 11, 2024 | investorplace.com7 Strong Buy Penny Stocks to Buy Now: June 2024June 13, 2024 | investorplace.comElite Pharmaceuticals, Inc.: Elite Pharmaceuticals Receives FDA Approval for Generic MethotrexateMay 20, 2024 | finanznachrichten.deElite global firm McKinsey in US Justice Department hot chair over Opioid crisisApril 26, 2024 | msn.comElite Pharmaceuticals, Inc. (ELTP)April 17, 2024 | finance.yahoo.comElite Pharmaceuticals, Inc. (PNK:ELTP) Q3 2024 Earnings Call TranscriptFebruary 16, 2024 | finance.yahoo.comElite Pharmaceuticals Inc Reports Significant Revenue and Operating Profit Growth in Q3 Fiscal 2024February 14, 2024 | finance.yahoo.comElite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call InformationFebruary 14, 2024 | finance.yahoo.comElite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024February 8, 2024 | finance.yahoo.comElite Pharmaceuticals (OTCMKTS:ELTP) Stock Price Crosses Above Fifty Day Moving Average of $0.16Elite Pharmaceuticals (OTCMKTS:ELTP) Shares Pass Above 50 Day Moving Average of $0.16February 6, 2024 | marketbeat.comElite Pharmaceuticals, Inc.January 15, 2024 | thestreet.comElite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System StimulantDecember 26, 2023 | finance.yahoo.comElite Pharmaceuticals makes first product shipment of generic Adderall XR to PrascoDecember 12, 2023 | msn.comElite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLCDecember 12, 2023 | finance.yahoo.comElite Pharmaceuticals Inc ELTPNovember 24, 2023 | morningstar.comElite Pharmaceuticals, Inc. (PNK:ELTP) Q2 2024 Earnings Call TranscriptNovember 20, 2023 | finance.yahoo.comElite Pharmaceuticals reports Q3 resultsNovember 14, 2023 | msn.comElite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call InformationNovember 14, 2023 | finance.yahoo.comElite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023November 10, 2023 | finance.yahoo.comElite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic ProductSeptember 25, 2023 | finance.yahoo.comElite Pharmaceuticals reappoints Carter Ward as CFOSeptember 7, 2023 | msn.comElite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial OfficerSeptember 7, 2023 | finance.yahoo.comElite Pharmaceuticals, Inc.: Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence StudyAugust 28, 2023 | finanznachrichten.deThis Week's Top OTC Nano-Caps (ATVK, ELTP, EBET, ENZC)August 28, 2023 | benzinga.comDiscover the Potential: "Top Penny Stocks to Watch Now": SNNC, TIVC, ENZC, ELTP, CLNVAugust 22, 2023 | benzinga.comElite Pharmaceuticals reports Q1 resultsAugust 14, 2023 | seekingalpha.comElite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call InformationAugust 14, 2023 | finance.yahoo.comElite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023August 9, 2023 | finance.yahoo.comElite Pharmaceuticals, Inc. (PNK:ELTP) Q4 2023 Earnings Call TranscriptJuly 2, 2023 | finance.yahoo.comElite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call InformationJune 29, 2023 | finance.yahoo.comELTP - Elite Pharmaceuticals, Inc.June 23, 2023 | finance.yahoo.comElite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2023 Financial Results on June 30, 2023June 22, 2023 | finance.yahoo.comElite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial OfficerMay 3, 2023 | finance.yahoo.comTrenbolone Enanthate Market 2023-2030April 21, 2023 | marketwatch.comElite Pharmaceuticals, Inc.: Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite ProductApril 20, 2023 | finanznachrichten.deElite Pharmaceuticals seeks FDA approval for generic antimetabolite drugApril 20, 2023 | msn.com Get Elite Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTP and its competitors with MarketBeat's FREE daily newsletter. Email Address Automatic Income (from home) (Ad)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part… Watch this short video ELTP Media Mentions By Week ELTP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELTP News Sentiment▼0.270.50▲Average Medical News Sentiment ELTP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELTP Articles This Week▼30▲ELTP Articles Average Week Get Elite Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amneal Pharmaceuticals News Zai Lab News Catalyst Pharmaceuticals News Iovance Biotherapeutics News Scholar Rock News Twist Bioscience News Protagonist Therapeutics News Janux Therapeutics News Longboard Pharmaceuticals News IDEAYA Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ELTP) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could...Investors Alley | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elite Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elite Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
